The Influence of Big (Clinical) Data and Genomics on Precision Medicine and Drug Development

Clinical Pharmacology and Therapeutics

Volumn 103, Issue 3, 2018, Pages 409-418

  Denny, Joshua C ^a   Van Driest, Sara L ^a   Wei, Wei Qi ^a   Roden, Dan M ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE DRUG REACTION; ARTICLE; BIG DATA; BIOBANK; CLINICAL STUDY; COHORT ANALYSIS; DRUG DEVELOPMENT; DRUG EFFECT; DRUG REPOSITIONING; DRUG TARGETING; ELECTRONIC HEALTH RECORD; GENETIC ASSOCIATION STUDY; GENOMICS; HISTORY; HUMAN; INFORMATION PROCESSING; LARGE SCALE PRODUCTION; MACHINE LEARNING; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHENOME WIDE ASSOCIATION STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; CLINICAL PHARMACOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRENDS;

BIG DATA; DRUG REPOSITIONING; ELECTRONIC HEALTH RECORDS; HUMANS; PHARMACOGENETICS; PHARMACOLOGY, CLINICAL; PRECISION MEDICINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85041566290     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.951     Document Type: Article

References (99)

1. Gottesman, O. et al. The Electronic Medical Records and Genomics (eMERGE) network: past, present, and future. Genet. Med. Off. J. Am. Coll. Med. Genet. 15, 761–771 (2013).
2. Sanseau, P. et al. Use of genome-wide association studies for drug repositioning. Nat. Biotechnol. 30, 317–320 (2012).
3. Nelson, M.R. et al. The support of human genetic evidence for approved drug indications. Nat. Genet. 47, 856–860 (2015).
4. Kathiresan, S. et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat. Genet. 40, 189–197 (2008).
5. Okada, Y. et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506, 376–381 (2014).
6. Florez, J.C. Mining the genome for therapeutic targets. Diabetes 66, 1770–1778 (2017).
7. Cohen, J. et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37, 161–165 (2005).
8. Cohen, J.C., Boerwinkle, E., Mosley, T.H.J. & Hobbs, H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264–1272 (2006).
9. Sabatine, M.S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 376, 1713–1722 (2017).
10. Holmes, M.V. et al. Mendelian randomization of blood lipids for coronary heart disease. Eur. Heart J. 36, 539–550 (2015).
11. Voight, B.F. et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet 380, 572–580 (2012).
12. Mohammadpour, A.H. & Akhlaghi, F. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective. Clin. Pharmacokinet. 52, 615–626 (2013).
13. HPS3/TIMI55 Group, Bowman, L. et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N. Engl. J. Med. 377, 1217–1227 (2017).
14. Elliott, P. et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 302, 37–48 (2009).
15. Kastelein, J.J.P. et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358, 1431–1443 (2008).
16. Myocardial Infarction Genetics Consortium Investigators et al. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N. Engl. J. Med. 371, 2072–2082 (2014).
17. Cannon, C.P. et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 372, 2387–2397 (2015).
18. Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators, Stitziel, N.O. et al. Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. N. Engl. J. Med. 374, 1134–1144 (2016).
19. Dewey, F.E. et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N. Engl. J. Med. 374, 1123–1133 (2016).
20. Nioi, P. et al. Variant ASGR1 associated with a reduced risk of coronary artery disease. N. Engl. J. Med. 374, 2131–2141 (2016).
21. Dewey, F.E. et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N. Engl. J. Med. 377, 211–221 (2017).
22. Graham, M.J. et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N. Engl. J. Med. 377, 222–232 (2017).
23. Schmidt, A.F. et al. PCSK9 genetic variants and risk of type 2 diabetes: a Mendelian randomisation study. Lancet Diabetes Endocrinol. 5, 97–105 (2017).
24. Weinshilboum, R.M. & Sladek, S.L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 32, 651–662 (1980).
25. Giacomini, K.M. et al. Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine. Nat. Rev. Drug Discov. 16, 70–70 (2017).
26. Delaney, J.T. et al. Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin. Pharmacol. Ther. 91, 257–263 (2012).
27. Ramirez, A.H. et al. Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics 13, 407–418 (2012).
28. Bowton, E. et al. Biobanks and electronic medical records: enabling cost-effective research. Sci. Transl. Med. 6, 234cm3 (2014).
29. Kirby, J.C. et al. PheKB: A catalog and workflow for creating electronic phenotype algorithms for transportability. J. Am. Med. Inform. Assoc. JAMIA 23, 1046–1052 (2016).
30. Mosley, J.D. et al. A genome-wide association study identifies variants in KCNIP4 associated with ACE inhibitor-induced cough. Pharmacogenomics J. 16, 231–237 (2016).
31. Van Driest, S.L. et al. Genome-wide association study of serum creatinine levels during vancomycin therapy. PloS One 10, e0127791 (2015).
32. Postmus, I. et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat. Commun. 5, 5068 (2014).
33. Wei, W.-Q. et al. Characterization of statin dose response in electronic medical records. Clin. Pharmacol. Ther. 95, 331–338 (2014).
34. Overby, C.L. et al. A collaborative approach to developing an electronic health record phenotyping algorithm for drug-induced liver injury. J. Am. Med. Inform. Assoc. 20, e243–e252 (2013).
35. Denny, J.C. et al. PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics 26, 1205–1210 (2010).
36. Pendergrass, S.A. et al. The use of phenome-wide association studies (PheWAS) for exploration of novel genotype-phenotype relationships and pleiotropy discovery. Genet. Epidemiol. 35, 410–422 (2011).
37. Denny, J.C. et al. Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat. Biotechnol. 31, 1102–1111 (2013).
38. Karnes, J.H. et al. Phenome-wide scanning identifies multiple diseases and disease severity phenotypes associated with HLA variants. Sci. Transl. Med. 9, (2017).
39. Bush, W.S., Oetjens, M.T. & Crawford, D.C. Unravelling the human genome-phenome relationship using phenome-wide association studies. Nat. Rev. Genet. 17, 129–145 (2016).
40. Diogo, D. et al. TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits. PLoS One 10, e0122271 (2015).
41. Rastegar-Mojarad, M., Ye, Z., Kolesar, J.M., Hebbring, S.J. & Lin, S.M. Opportunities for drug repositioning from phenome-wide association studies. Nat. Biotechnol. 33, 342–345 (2015).
42. Brownstein, J.S., Sordo, M., Kohane, I.S. & Mandl, K.D. The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction. PLoS One 2, e840 (2007).
43. LePendu, P. et al. Pharmacovigilance using clinical notes. Clin. Pharmacol. Ther. 93, 547–555 (2013).
44. Leeper, N.J. et al. Practice-based evidence: profiling the safety of cilostazol by text-mining of clinical notes. PLoS One 8, e63499 (2013).
45. Tatonetti, N.P. et al. Detecting drug interactions from adverse-event reports: Interaction between paroxetine and pravastatin increases blood glucose levels. Clin. Pharmacol. Ther. 90, 133–142 (2011).
46. Xu, H. et al. Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. J. Am. Med. Inform. Assoc. 22, 179–191 (2015).
47. Zhang, P., Li, H., Tan, X., Chen, L. & Wang, S. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol. 37, 207–218 (2013).
48. Nielsen, S.F., Nordestgaard, B.G. & Bojesen, S.E. Statin use and reduced cancer-related mortality. N. Engl. J. Med. 367, 1792–1802 (2012).
49. Seckl, M.J. et al. Multicenter, phase III, randomized, double-blind, placebo-controlled trial of pravastatin added to first-line standard chemotherapy in small-cell lung cancer (LUNGSTAR). J. Clin. Oncol. 35, 1506–1514 (2017).
50. Emilsson, L. et al. Examining bias in studies of statin treatment and survival in patients with cancer. JAMA Oncol. doi: 10.1001/jamaoncol.2017.2752 (2017) [Epub ahead of print].
51. Raymakers, A.J.N., Sadatsafavi, M., Sin, D.D., Vera, M.A.D. & Lynd, L.D. The impact of statin drug use on all-cause mortality in patients with COPD. Chest 152, 486–493 (2017).
52. Savova, G.K., Ogren, P.V., Duffy, P.H., Buntrock, J.D. & Chute, C.G. Mayo Clinic NLP system for patient smoking status identification. J. Am. Med. Inf. Assoc 15, 25–28 (2008).
53. Cohen, A.M. Five-way smoking status classification using text hot-spot identification and error-correcting output codes. J. Am. Med. Inf. Assoc 15, 32–35 (2008).
54. Pakhomov, S.V.S., Hanson, P.L., Bjornsen, S.S. & Smith, S.A. Automatic classification of foot examination findings using clinical notes and machine learning. J. Am. Med. Inform. Assoc. 15, 198–202 (2008).
55. Jiang, M. et al. A study of machine-learning-based approaches to extract clinical entities and their assertions from discharge summaries. J. Am. Med. Inform. Assoc. 18, 601–606 (2011).
56. Pakhomov, S.V., Buntrock, J.D. & Chute, C.G. Automating the assignment of diagnosis codes to patient encounters using example-based and machine learning techniques. J. Am. Med. Inf. Assoc 13, 516–25 (2006).
57. Savova, G.K. et al. Mayo clinical Text Analysis and Knowledge Extraction System (cTAKES): architecture, component evaluation and applications. J. Am. Med. Inform. Assoc. 17, 507–513 (2010).
58. Chen, Y., Lasko, T.A., Mei, Q., Denny, J.C. & Xu, H. A study of active learning methods for named entity recognition in clinical text. J. Biomed. Inform. 58, 11–18 (2015).
59. Carroll, R.J., Eyler, A.E. & Denny, J.C. Naïve electronic health record phenotype identification for rheumatoid arthritis. AMIA Annu. Symp. Proc. 2011, 189–196 (2011).
60. Liao, K.P. et al. Electronic medical records for discovery research in rheumatoid arthritis. Arthritis Care Res. 62, 1120–1127 (2010).
61. Lin, C. et al. Automatic identification of methotrexate-induced liver toxicity in patients with rheumatoid arthritis from the electronic medical record. J. Am. Med. Inform. Assoc. 22, e151–161 (2015).
62. Lin, C. et al. Automatic prediction of rheumatoid arthritis disease activity from the electronic medical records. PLoS One 8, e69932 (2013).
63. Le, Q.V. et al. Building high-level features using large scale unsupervised learning. ArXiv11126209 Cs (2011).
64. Lasko, T.A., Denny, J.C. & Levy, M.A. Computational phenotype discovery using unsupervised feature learning over noisy, sparse, and irregular clinical data. PLoS One 8, e66341 (2013).
65. Gulshan, V. et al. Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. JAMA 316, 2402–2410 (2016).
66. Esteva, A. et al. Dermatologist-level classification of skin cancer with deep neural networks. Nature 542, 115–118 (2017).
67. Khozin, S., Blumenthal, G.M. & Pazdur, R. Real-world data for clinical evidence generation in oncology. J. Natl. Cancer Inst. 109, (2017).
68. FDA's Sentinel Initiative. . Accessed 11 November 2017.
69. Khozin, S., Kim, G. & Pazdur, R. Regulatory watch: From big data to smart data: FDA's INFORMED initiative. Nat. Rev. Drug Discov. 16, nrd.2017.26 (2017).
70. IBM's Watson can improve cancer treatment through better gene targeting. ScienceDaily . Accessed 11 November 2017.
71. MD Anderson Cancer Center's IBM Watson project fails, and so did the journalism related to it. HealthNewsReview.org
72. Codella, N.C.F. et al. Deep learning ensembles for melanoma recognition in dermoscopy images. IBM J. Res. Dev. 61, 5:1-5:15 (2017).
73. Li, L. et al. Identification of type 2 diabetes subgroups through topological analysis of patient similarity. Sci. Transl. Med. 7, 311ra174–311ra174 (2015).
74. Doshi-Velez, F., Ge, Y. & Kohane, I. Comorbidity clusters in autism spectrum disorders: an electronic health record time-series analysis. Pediatrics 133, e54–63 (2014).
75. Lingren, T. et al. Electronic health record based algorithm to identify patients with autism spectrum disorder. PLoS One 11, e0159621 (2016).
76. Ho, J.C. et al. Limestone: High-throughput candidate phenotype generation via tensor factorization. J. Biomed. Inform. 52, 199–211 (2014).
77. Plenge, R.M., Scolnick, E.M. & Altshuler, D. Validating therapeutic targets through human genetics. Nat. Rev. Drug Discov. 12, 581–594 (2013).
78. Plumpton, C.O., Roberts, D., Pirmohamed, M. & Hughes, D.A. A systematic review of economic evaluations of pharmacogenetic testing for prevention of adverse drug reactions. PharmacoEconomics 34, 771–793 (2016).
79. Marouli, E. et al. Rare and low-frequency coding variants alter human adult height. Nature 542, 186–190 (2017).
80. Rosenbloom, S.T., Carroll, R.J., Warner, J.L., Matheny, M.E. & Denny, J.C. Representing knowledge consistently across health systems. Yearb. Med. Inform. 26, 139–147 (2017).
81. Hripcsak, G. et al. Characterizing treatment pathways at scale using the OHDSI network. Proc. Natl. Acad. Sci. U. S. A. 113, 7329–7336 (2016).
82. Collins, F.S., Hudson, K.L., Briggs, J.P. & Lauer, M.S. PCORnet: turning a dream into reality. J. Am. Med. Inform. Assoc. 21, 576–577 (2014).
83. O'Donnell, P.H. et al. The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin. Pharmacol. Ther. 92, 446–449 (2012).
84. Pulley, J.M. et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT Project. Clin. Pharmacol. Ther. 92, 87–95 (2012).
85. Weitzel, K.W. et al. Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am. J. Med. Genet. C Semin. Med. Genet. 166, 56–67 (2014).
86. Larson, E.A. & Wilke, R.A. Integration of genomics in primary care. Am. J. Med. (2015).
87. Weitzel, K.W. et al. The IGNITE network: a model for genomic medicine implementation and research. BMC Med. Genomics 9, 1 (2016).
88. Cavallari, L.H. et al. Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. JACC Cardiovasc. Interv. doi: 10.1016/j.jcin.2017.07.022 (2017) [Epub ahead of print].
89. Peterson, J.F. et al. Physician response to implementation of genotype-tailored antiplatelet therapy. Clin. Pharmacol. Ther. 100, 67–74 (2016).
90. Gaziano, J.M. et al. Million Veteran Program: a mega-biobank to study genetic influences on health and disease. J. Clin. Epidemiol. 70, 214–223 (2016).
91. Chen, Z. et al. China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up. Int. J. Epidemiol. 40, 1652–1666 (2011).
92. Sudlow, C. et al. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 12, e1001779 (2015).
93. Precision Medicine Initiative (PMI) Working Group Report to the Advisory Committee to the Director, NIH. The Precision Medicine Initiative Cohort Program – Building a Research Foundation for 21st Century Medicine.
94. Vear, S.I. et al. The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population. Br. J. Haematol. 165, 832–835 (2014).
95. Birdwell, K.A. et al. The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. Pharmacogenet. Genomics 22, 32–42 (2012).
96. Wells, Q.S. et al. Genome-wide association and pathway analysis of left ventricular function after anthracycline exposure in adults. Pharmacogenet. Genomics 27, 247–254 (2017).
97. Kawai, V.K. et al. Genotype and risk of major bleeding during warfarin treatment. Pharmacogenomics 15, 1973–1983 (2014).
98. Feng, Q. et al. The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy. Pharmacogenomics J. 17, 204–208 (2017).
99. Karnes, J. H. et al. A genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record. Thromb. Haemost. 113 (2014).